Isis set for milestone payment from Biogen

Isis Pharmaceuticals (NASDAQ:ISIS) plans to dose the first patient in the next few weeks in a Phase 3 clinical trial evaluating the safety and efficacy of ISIS-SMNrx in infants with spinal muscular atrophy (SMA). This event will trigger an $18M milestone payment from development partner Biogen (NASDAQ:BIIB).

The primary endpoint of the 110-infant study is survival or permanent ventilation.

From other sites
Comments (3)
  • Wall Street Sleuth
    , contributor
    Comments (100) | Send Message
    Great news for patients and investors.
    1 Aug 2014, 08:34 AM Reply Like
  • papita
    , contributor
    Comments (429) | Send Message
    great to see there are people out there who comment on this wonderful news. renews my faith in man. long BIIB.
    1 Aug 2014, 08:44 AM Reply Like
  • rstran
    , contributor
    Comments (152) | Send Message
    Stock did not move on the news. Same for the last 1m milestone last week
    2 Aug 2014, 04:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs